Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
Immunotherapy in Prostate Cancer
June 30th 2015Maha H. Hussain, MD, professor of Medicine and Urology, University of Michigan, associate director, Clinical Research, co-leader, Prostate Cancer/GU Oncology Program, assistant chief, Clinical Research at the Division of Hematology/ Oncology, University of Michigan Comprehensive Cancer Center, discusses immunotherapy in prostate cancer.
Watch
Ipilimumab Combined With Nivolumab for the Treatment of Patients With Melanoma
June 30th 2015Anna C. Pavlick, MD, associate professor, co-director, Melanoma Program, assistant director, Clinical Research Education, discusses a study that examined two immunotherapy agents, ipilimumab and nivolumab, in patients with melanoma.
Watch
Pembrolizumab in Urothelial Cancer
June 26th 2015Elizabeth Plimack, MD, MS, attending physician, genitourinary cancer associate professor, Medical Oncology Director of Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a study that examined pembrolizumab in patients with urothelial cancer.
Watch
Phase IA Study of Atezolizumab in Urothelial Bladder Cancer
June 26th 2015Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses a phase Ia study examining atezolizumab in patients with urothelial bladder cancer.
Watch
Afatinib Versus Erlotinib in Advanced SCC of the Lung
June 24th 2015Shirish Gadgeel, MD, Barbara Ann Karmanos Cancer Institute, discusses a phase III study examining afatinib versus erlotinib as a second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy.
Watch
Next Steps Following PALOMA3 Trial for Breast Cancer
June 23rd 2015Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, Jefferson University Hospital, discusses the next steps following the PALOMA3 trial, which was a randomized, placebo-controlled phase III study examining palbociclib plus fulvestrant in pre- and post-menopausal patients with ER-positive breast cancer.
Watch
Abiraterone With Low-Dose Prednisone in Patients With Prostate Cancer
June 22nd 2015Joseph F. Renzulli, II, MD, FACS, assistant professor of Surgery, (Urology), Alpert Medical School, Brown University, discusses a phase II study that examined the use of abiraterone acetate with low-dose prednisone in patients with prostate cancer.
Watch
Combination of Panobinostat and Carfilzomib in Relapsed or Relapsed/Refractory Multiple Myeloma
June 19th 2015Jesus G. Berdeja, MD, director of Myeloma Research, senior investigator, Hematologic Malignancies Principal Investigator, Sarah Cannon Research Institute, discusses a phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma.
Watch
Effect of Anamorelin on Cachexia in Advanced NSCLC
June 18th 2015Jennifer S. Temel, clinical director, Thoracic Oncology, Massachusetts General Hospital, discusses a phase III study that examined the impact of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia.
Watch
ONT-380 in Combination With Capecitabine and Trastuzumab in HER2-Positive Breast Cancer
June 15th 2015Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase 1b study examining ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine and trastuzumab in the third-line setting and treatment of HER2-positive metastatic breast cancer.
Watch
Urine Assay as Test for High-Grade Prostate Cancer
June 12th 2015James M. Kiernan, MD, professor of Urology and director of Urologic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center in New York, discusses EXO106, a urine assay, as a promising test for high-grade prostate cancer.
Watch
Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma
June 11th 2015Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).
Watch
Patients With Ovarian Cancer Likely to Respond to Rucaparib Using Tumor Genetic Analysis
June 10th 2015Robert L. Coleman, MD, FACOG, FACS, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the results of the ARIEL2 trial, a phase II study to identify patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis.
Watch
Functional Genomics of Barrett's Esophagus and Esophageal Adenocarcinoma
May 16th 2015Adam J. Bass, MD, assistant professor, Department of Medicine, Harvard Medical School, assistant professor of medicine, Division of Cellular and Molecular Oncology, Dana-Farber Cancer Institute, discusses functional genomics of Barrett's esophagus and esophageal adenocarcinoma.
Watch
Patient Selection for the Treatment of Myeloma
April 30th 2015Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses patient selection for the treatment of myeloma, especially relapsed myeloma.
Watch
Advances in Relapsed Multiple Myeloma
April 14th 2015Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses advances in the management of relapsed multiple myeloma.
Watch